This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1 AK Cheung , MJ Sarnak , G Yan , (2004) Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 65, 2380–2389.
2 MJ Sarnak , AS Levey , AC Schoolwerth , (2003) Kidney disease as a risk factor for the development of cardiovascular disease. Circulation 108, 2154–2169.
3 AS Go , GM Chertow & D Fan (2004) Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 351, 1296–1305.
4 JW Eikelboom , EM Lonn , J Genest , (1999) Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131, 363–375.
5 B Bayes , MC Pastor , J Bonal , (2005) New cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment. Kidney Int Suppl S39–S43.
6 F Wollesen , B Brattstrom , H Refsum , (1999) Plasma total homocysteine and cystein in relation to glomerular filtration rate. Kidney Int 55, 1028–1035.
7 F Mallamaci , C Zoccali , G Tripepi , (2002) Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61, 609–614.
10 LA Bazzano , K Reynolds , KN Holder , (2006) Effect of folic acid supplementation on the risk of cardiovascular diseases. JAMA 296, 2720–2726.
11 ME Suliman , B Lindholm , P Barany , (2007) Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin Dial 20, 523–529.
12 S Zoungas , BP McGrath , P Branley , (2006) Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure – a multicenter, randomized, controlled trial. J Am Coll Cardiol 47, 1108–1116.
13 EM Wrone , JM Homberger , JL Zehnder , (2004) Randomized trial of folic acid for prevention of cardiovascular events in end stage renal disease. J Am Soc Nephrol 15, 420–426.
14 M Righetti , P Serbelloni , S Milani , (2006) Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 24, 379–386.
15 X Qin , Y Huo , CB Langman , (2011) Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 6, 482–488.
17 AC Vianna , AJ Mocelin , T Matsuo , (2007) Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 11, 210–216.
19 JFE Mann , P Sheridan , MJ McQueen , (2008) Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease – results of the renal Hope-2 study. Nephrol Dial Transplant 23, 645–653.
20 RL Jamison , P Hartigan , JS Kaufman , (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298, 1163–1170.
21 AA House , M Eliasziw , DC Cattran , (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303, 1603–1609.
22 J Heinz , S Kropf , U Domröse , (2010) B-vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease results of a randomized controlled trial. Circulation 121, 1432–1438.
23 ME Widlansky , N Gokce , JF Keaney , (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42, 1149–1160.
24 V Schachinger , MB Britten & AM Zeiher (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899–1906.
25 S Tatematsu , S Wakino , T Kanda , (2007) Role of nitric oxide producing and degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 18, 741–749.
27 C van Guldener , MJ Janssen , J Lambert , (1998) No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in hemodialysis patients. Nephrol Dial Transplant 13, 106–112.
28 M Arnadottir , V Gudnason & B Hultberg (2000) Treatment with different doses of folic acid in hemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant 15, 524–528.
29 CJ Boushey , SA Beresford , GS Omenn , (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049–1057.
30 R Tremblay , A Bonnardeaux , D Geadah , (2000) Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 58, 851–858.
31 S Billion , B Tribout , E Cadet , (2002) Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12. Nephrol Dial Transplant 17, 455–461.
32 M Födinger , C Mannhalter , G Wölfl , (1997) Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52, 517–523.
33 AA House , GA Wells , JG Donnelly , (2000) Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 15, 1029–1034.
34 S Biasioli , R Schiavon , L Petrosino , (1998) Dialysis kinetics of homocysteine and reactive oxygen species. ASAIO J 44, M423–M432.
35 F Galli , S Benedetti , U Buoncristiani , (2003) The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 64, 748–755.
36 DW Mudge , R Rogers , P Hollett , (2005) Randomized trial of FX high flux vs. standard high flux dialysis for homocysteine clearance. Nephrol Dial Transplant 20, 2178–2185.
38 MR Mehrabi , K Huber , N Serbecic , (2002) Enrichment of homocysteine in coronary arteries of patients with coronary artery disease. Thromb Res 107, 189–196.
39 AR Jadad , RA Moore , D Carroll , (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1–12.
40 M Ebbing , KH Bønaa , O Nygård , (2009) Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302, 2119–2126.